Highlight
• Continuous glucose monitoring (CGM) detects subtle glucose abnormalities in children with cystic fibrosis (CF) before overt diabetes develops.
• The CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) improves glucose control metrics measured by CGM in pediatric patients.
• Early glucose abnormalities (time above 140 mg/dL >10%) correlate with less clinical improvement in lung function and weight after ETI initiation.
• CGM offers a sensitive tool to monitor metabolic changes and may inform prognosis and management in youth with CF undergoing ETI therapy.
